234 related articles for article (PubMed ID: 23645741)
1. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
[TBL] [Abstract][Full Text] [Related]
4. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
[TBL] [Abstract][Full Text] [Related]
8. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.
Wang T; Chuan Pan C; Rui Yu J; Long Y; Hong Cai X; De Yin X; Qiong Hao L; Li Luo L
PLoS One; 2013; 8(9):e74284. PubMed ID: 24040222
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
11. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
Pistillucci G; Sciacca V; Ciorra A; Di Palma T; Calabretta F; Lugini A; Rossi R; D'Aprile M; Veltri E
Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749
[TBL] [Abstract][Full Text] [Related]
12. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Sun JM; Han J; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
[TBL] [Abstract][Full Text] [Related]
13. [A brief overview of a lung cancer biomarker: thymidylate synthase].
Rouquette I; Mazieres J
Rev Mal Respir; 2011 Jun; 28(6):773-7. PubMed ID: 21742238
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
17. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-GarcĂa MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
20. Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
Takeda M; Okamoto I; Sakai K; Tanaka K; Terashima M; Nishio K; Nakagawa K
Clin Lung Cancer; 2012 Mar; 13(2):157-9. PubMed ID: 22056890
[No Abstract] [Full Text] [Related]
[Next] [New Search]